BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30993902)

  • 1. HPV-vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level.
    Altobelli E; Rapacchietta L; Profeta VF; Fagnano R
    Cancer Med; 2019 May; 8(5):2524-2534. PubMed ID: 30993902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.
    Bruni L; Diaz M; Barrionuevo-Rosas L; Herrero R; Bray F; Bosch FX; de Sanjosé S; Castellsagué X
    Lancet Glob Health; 2016 Jul; 4(7):e453-63. PubMed ID: 27340003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
    Spayne J; Hesketh T
    BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
    Sharma M; Seoud M; Kim JJ
    Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
    Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
    Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
    Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
    Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical cancer elimination in Italy: Current scenario and future endeavors for a value based prevention.
    Calabrò GE; Riccardi MT; D'Ambrosio F; Castagna C; Sapienza M; Millevolte R; Pellacchia A; Ricciardi R; de Vincenzo RP; de Waure C
    Front Public Health; 2022; 10():1010237. PubMed ID: 36530690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Implementation of National Cervical Cancer Screening Program in France].
    Woronoff AS; Molinié F; Trétarre B
    Bull Cancer; 2019 Mar; 106(3):253-261. PubMed ID: 30635113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social determinants of community-level human papillomavirus vaccination coverage in aschool-based vaccination programme.
    Jean S; Elshafei M; Buttenheim A
    Sex Transm Infect; 2018 Jun; 94(4):248-253. PubMed ID: 29330310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination coverage rates and predictors of HPV vaccination among eligible and non-eligible female adolescents at the Brazilian HPV vaccination public program.
    Faisal-Cury A; Levy RB; Tourinho MF; Grangeiro A; Eluf-Neto J
    BMC Public Health; 2020 Apr; 20(1):458. PubMed ID: 32252705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.